Kallyope, Inc.

About Kallyope, Inc.

Kallyope is a biotechnology company focused on discovering and developing novel therapeutics for neurological and metabolic diseases. Their mission is to address significant health challenges faced by patients and families, aiming to create effective, easy-to-use, and well-tolerated treatments.

Products & Services

Neurological and Metabolic Therapeutics:Medicines targeting neurological disorders such as migraine and pain, and metabolic conditions like type 2 diabetes and obesity.

Klarity™ Platform:A technology platform that integrates various technologies to enable the discovery and development of differentiated novel therapeutics.

Specialties

Neurological Diseases Metabolic Diseases Type 2 Diabetes Obesity Migraine Pain Drug Discovery and Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 8200000 MR: - FA: $8.2 million FAN: 8200000	D: 2023-05-10 FD: 2023-05-10	1 investors

Grant Latest

2023-05-10

$8.2M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jay Galeota

CEO & President

P

Patrick Flanigan

Chief Financial Officer

B

Brett Lauring

Chief Medical Officer

S

Shirly Pinto

Chief Scientific Officer

I

Iyassu Sebhat

SVP, Preclinical Development

G

George Shiebler

General Counsel

View 24 more team members with Pro

Unlock Full Team Directory

Recent News

Kallyope, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised